Risk Scores 101: What They Are & Why They Matter in Digital Health

A photo of a woman with a smartwatch

Risk scores have become an essential tool in healthcare, helping providers, insurers, and researchers estimate the likelihood of conditions and divide patients into risk groups. These tools can drive early interventions, reduce costs, and improve patient outcomes. But what happens when validated risk scores do not yet exist for certain conditions, or when organizations want to test new approaches before committing to large-scale clinical validation? At Thryve, we explore this through investigative prototypes—demonstrations of how wearable-derived data can be mapped to known risk factors and applied at the population scale.

Today, we explore what risk scores are and why they are so important for preventive health. Moreover, we illustrate our investigative approach using two conditions of growing importance: NASH (Non-Alcoholic Steatohepatitis) and Insomnia.  These examples illustrate how we map known risk factors to wearable data and apply them to large-scale populations in order to visualize potential risk groups.

What Are Risk Scores 

Risk scores are statistical tools designed to estimate the likelihood of an individual developing a specific disease or experiencing a health condition. They are widely used in healthcare to guide clinical decision-making, identify high-risk patients for early intervention, and allocate resources more efficiently. A risk score typically aggregates multiple variables into a single predictive number that can be compared across individuals or populations. These may include demographics, family history, lifestyle behaviors, comorbidities, or biometric data from clinical exams and wearables.

Examples of validated tools include the Framingham Risk Score for predicting cardiovascular disease and the CHA₂DS₂-VASc Score for assessing stroke risk in patients with atrial fibrillation. These scores are not diagnostic instruments but predictive aids that help clinicians, insurers, and policymakers focus attention and preventive strategies where they will have the greatest impact. They also create a shared language between stakeholders, allowing consistent comparisons and benchmarks across large populations.

Why Prototype Risk Scores Matter

Healthcare organizations often struggle with speed when it comes to data-driven innovation. Building validated scores requires years of clinical research, but many stakeholders, from insurers to digital health startups, need fast, data-backed signals to test ideas, design interventions, or explore new markets. Investigative risk scores fill this gap.

By mapping known risk factors to wearable metrics, Thryve demonstrates how hypotheses can be tested rapidly against population-level data. This allows organizations to:

  • Assess the feasibility of new health models.
  • Visualize risk distributions within weeks.
  • Explore how wearable metrics correlate with known conditions.
  • Lay the foundation for validated, clinical-grade tools in the future.

Importantly, risk scores matter because they enable proactive healthcare by providing an early warning system that highlights who might benefit from additional testing, closer monitoring, or lifestyle interventions before costly or severe health events occur. This investigative-first approach helps partners derisk innovation, cut infrastructure costs, and focus on what really matters: translating data into decisions.

Thryve’s Risk Scores Cases 

At Thryve. We support the development of investigative risk scores. We do this to help our partners quickly explore how wearable-derived data can be applied to pressing health questions without the long timelines of traditional validation studies. To showcase this capability, we have built two case studies: one focused on NASH (Non-Alcoholic Steatohepatitis) and one on Insomnia. These are not validated clinical scores, but rather prototypes that showcase how quickly Thryve can deliver actionable insights by leveraging wearable data across tens of thousands of users. For digital health organizations, the message is clear: if you have a specific health problem, Thryve can build a working data prototype within weeks, not months. 

Case 1: Investigating Risk for NASH (Non-Alcoholic Steatohepatitis)

NASH is a progressive liver disease strongly linked to obesity, diabetes, and metabolic syndrome. It is often called a silent disease, as symptoms are minimal until significant liver damage has occurred. Traditional screening methods are invasive, costly, and not scalable. This makes NASH a perfect candidate to test whether wearable-derived data can help identify risk groups earlier.

In our prototype investigation, we mapped known NASH risk factors to wearable and lifestyle data streams:

  • Resting heart rate & HRV: Indicators of metabolic stress and autonomic dysfunction.
  • Daily activity levels & sedentary minutes: Lifestyle contributors tied to obesity and insulin resistance.
  • Sleep duration and efficiency: Chronic poor sleep is linked to metabolic dysfunction.
  • Sociodemographic inputs: Self-reported BMI, diabetes, hypertension, and age.

Two types of scoring were applied:

  1. Absolute scoring: Assigned risk strictly based on known thresholds (e.g., BMI ≥ 30). About 71% of users were classified as low risk, with only a small high-risk group emerging.
  2. Relative scoring: Compared users against the population distribution. Here, about 32% were classified as higher risk, revealing a much broader at-risk population.

The divergence between absolute and relative scoring illustrates both the potential and the limitations of early-stage approaches. While absolute scoring aligns with clinical benchmarks, relative scoring highlights patterns within large datasets that might otherwise remain invisible. This dual perspective is invaluable for organizations exploring population health strategies.

Case 2: Investigating Risk for Insomnia

Insomnia, on the other hand, is one of the most common sleep disorders, affecting millions worldwide, yet it remains underdiagnosed and undertreated. Wearable devices, with their ability to track sleep behavior objectively, open up new ways of identifying at-risk populations.

For our prototype insomnia risk score, we drew on known risk factors:

  • Short sleep duration (<6h/night).
  • Sleep latency (>15 minutes to fall asleep).
  • Frequent awakenings (>3 per night).
  • Reduced sleep efficiency.

The results were insightful:

  • 65% were classified as low risk, displaying healthy sleep patterns.
  • 34% fell into a moderate risk group, showing consistent disruptions or insufficient sleep.
  • 0.1% were high risk, displaying significant markers of chronic insomnia.

Although not validated, this prototype stratification highlighted clear behavioral clusters. For instance, users with consistently short sleep paired with high stress markers (low HRV) aligned with known insomnia risk groups. Such insights demonstrate how wearables can provide scalable screening tools and open the door to early interventions.

Key Learnings from the Prototypes

Both NASH and Insomnia cases illustrate important lessons that highlight not just technical feasibility but also strategic implications for healthcare organizations:

  • Wearables provide scalable data access: Continuous signals such as heart rate, sleep patterns, and activity levels are available across populations and can be compared longitudinally. This scale allows trends to be detected far earlier than traditional surveys or episodic check‑ups.
  • Prototyping is fast and efficient: With Thryve’s infrastructure, building and applying a prototype model to >10,000 users is achievable within weeks. This speed matters for partners who want to explore hypotheses, test prevention strategies, or quickly validate whether an approach is worth deeper clinical study.
  • Insights emerge even without validation: Population-level distributions can highlight clear clusters, correlations, and behavioral patterns. These findings help customers refine interventions, design targeted outreach, and identify which groups might warrant further clinical research.
  • Limitations must be clear and transparent: These prototypes are investigative, not diagnostic. It is essential to communicate that they are conceptual explorations, avoiding misinterpretation and ensuring they are used as a starting point for innovation, not as final clinical tools.
  • Customer value is tangible: By using investigative prototypes, insurers, providers, or research partners can reduce infrastructure costs, shorten timelines, and make informed go/no-go decisions earlier in the process. This creates room for faster innovation cycles while keeping risk manageable.

How Thryve Utilizes Risk Scores 

NASH and Insomnia are just two examples of how Thryve can prototype risk scores quickly, using wearable-derived data to explore known risk factors and visualize population-level insights. Thryve’s API is uniquely suited to powering these prototypes:

  • Seamless Device Integration: Easily connect over 500 other health monitoring devices to your platform, eliminating the need for multiple integrations.
  • Standardized Biometric Models: Automatically harmonize biometric data streams, including heart rate, sleep metrics, skin temperature, activity levels, and HRV, making the data actionable and consistent across devices.
  • GDPR-Compliant Infrastructure: Ensure full compliance with international privacy and security standards, including GDPR and HIPAA. All data is securely encrypted and managed according to the highest privacy requirements.  

For potential partners, this means reduced infrastructure costs, faster turnaround times, and the confidence that your prototypes are built on reliable, harmonized data.

Book a demo with Thryve today and learn how we help you uncover risk groups, test ideas, and turn health data into actionable insights!